Amgen Inc. (ETR:AMG)
Germany · Delayed Price · Currency is EUR | Market Cap | 233.32B +54.7% |
| Revenue (ttm) | 34.26B +8.2% |
| Net Income | 8.27B +34.1% |
| EPS | 15.55 +33.5% |
| Shares Out | n/a |
| PE Ratio | 27.35 |
| Forward PE | 19.27 |
| Dividend | 8.70 (2.05%) |
| Ex-Dividend Date | Nov 20, 2026 |
| Volume | 563 |
| Open | 426.45 |
| Previous Close | 416.10 |
| Day's Range | 420.90 - 427.20 |
| 52-Week Range | 267.60 - 438.75 |
| Beta | 0.42 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 3, 2026 |
About Amgen
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascul... [Read more]
Financial Performance
In 2025, Amgen's revenue was $36.75 billion, an increase of 9.95% compared to the previous year's $33.42 billion. Earnings were $7.71 billion, an increase of 88.53%.
Financial numbers in USD Financial StatementsNews
Amgen price target raised to $515 from $460 at Argus
Argus raised the firm’s price target on Amgen (AMGN) to $515 from $460 and keeps a Buy rating on the shares. The company has a strong pipeline of potential new…
Amgen's experimental Sjogren's drug meets late-stage trial goal
Amgen said on Wednesday its experimental drug showed sustained reduction in disease activity in a late-stage study of patients with Sjogren's disease, an autoimmune condition.
Amgen reports results from Phase 3 OASIZ-301 study of dazodalibep
Amgen (AMGN) announced results from the Phase 3 OASIZ-301 study of dazodalibep, the only global Phase 3 trial to demonstrate clinically meaningful improvements in systemic disease activity and symptom...
AMGEN ANNOUNCES POSITIVE PHASE 3 RESULTS FOR DAZODALIBEP IN SJÖGREN'S DISEASE
Only Global Phase 3 Trial to Show Clinically Meaningful Improvements in Systemic Disease Activity and Patient-Reported Symptoms of Sjögren's Disease THOUSAND OAKS, Calif., Nov. 11, 2026 /PRNewswire/ -...
Amgen’s Repatha shows cost-effectiveness in cardiovascular study
Amgen (AMGN) announced new data at the American Heart Association Scientific Sessions 2026 that further strengthen the case for more intensive lowering of low-density lipoprotein cholesterol, or LDL-C...
NEW DATA AT AHA 2026 DEMONSTRATES THE VALUE OF TREATMENT WITH REPATHA® EARLIER IN THE CARDIOVASCULAR RISK CONTINUUM
Independent VESALIUS-CV Analysis Finds Repatha Highly Cost-Effective in High-Risk Patients Without a Prior Heart Attack or Stroke Long-Term FOURIER External-Control Analysis Shows Repatha Associated W...
Novartis drops heart drug after it failed to prevent heart attacks
Novartis is ending development of pelacarsen in heart disease. In a study of more than 8,300 patients the drug cut Lp(a) levels by 78% but did not reduce heart attacks or strokes.
Amgen downgraded to Hold from Buy at Freedom Broker
Freedom Broker downgraded Amgen (AMGN) to Hold from Buy with a price target of $470, up from $450. The firm views the company’s Q3 report as strong. Freedom cites valuation…
Amgen’s Repatha lowers heart attack risk 20% vs. ezetimibe in real-world study
Amgen (AMGN) announced results from a large real-world study showing that treatment with Repatha – evolocumab – reduced the risk of fatal or nonfatal heart attacks by 20% compared with…
REPATHA® LOWERS RISK OF HEART ATTACKS BY 20% COMPARED WITH EZETIMIBE IN A LARGE REAL-WORLD STUDY
Findings Represent Largest and Most Rigorous Head-to-Head Real-World Outcomes Analysis of Repatha and Ezetimibe Study Examined More Than Half a Million Adults Living with Heart Disease Results Provid...
Amgen price target raised to $435 from $378 at Guggenheim
Guggenheim analyst Vamil Divan raised the firm’s price target on Amgen (AMGN) to $435 from $378 and keeps a Neutral rating on the shares.
Amgen price target raised to $530 from $500 at Scotiabank
Scotiabank analyst Louise Chen raised the firm’s price target on Amgen (AMGN) to $530 from $500 and keeps an Outperform rating on the shares. The firm believes the company’s commercial…
Amgen price target raised to $398 from $380 at Truist
Truist analyst Gregory Renza raised the firm’s price target on Amgen (AMGN) to $398 from $380 and keeps a Hold rating on the shares. The firm is positive on the…
Amgen price target raised to $470 from $430 at RBC Capital
RBC Capital analyst Luca Issi raised the firm’s price target on Amgen (AMGN) to $470 from $430 and keeps an Outperform rating on the shares. The company delivered a meaningful…
Amgen price target raised to $520 from $480 at Oppenheimer
Oppenheimer analyst Jay Olson raised the firm’s price target on Amgen (AMGN) to $520 from $480 and keeps an Outperform rating on the shares following quarterly results. The firm notes…
Amgen price target raised to $531 from $452 at TD Cowen
TD Cowen raised the firm’s price target on Amgen (AMGN) to $531 from $452 and keeps a Buy rating on the shares. The firm updated its model following its 3rd…
Amgen price target raised to $410 from $359 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Amgen (AMGN) to $410 from $359 and keeps an Equal Weight rating on the shares.
Amgen price target raised to $347 from $328 at BofA
BofA raised the firm’s price target on Amgen (AMGN) to $347 from $328 and keeps an Underperform rating on the shares after the firm adjusted estimates for Q3 results, product…
Amgen price target raised to $530 from $470 at UBS
UBS raised the firm’s price target on Amgen (AMGN) to $530 from $470 and keeps a Buy rating on the shares. Amgen beat Q3 revenue and EPS estimates and raised…
Amgen price target raised to $465 from $440 at Cantor Fitzgerald
Cantor Fitzgerald analyst Carter Gould raised the firm’s price target on Amgen (AMGN) to $465 from $440 and keeps a Neutral rating on the shares. Amgen delivered broad product-level beats,…
Amgen price target raised to $400 from $345 at Bernstein
Bernstein raised the firm’s price target on Amgen (AMGN) to $400 from $345 and keeps a Market Perform rating on the shares. The firm notes Amgen delivered a 3.4% revenue…
Amgen price target raised to $425 from $350 at JPMorgan
JPMorgan raised the firm’s price target on Amgen (AMGN) to $425 from $350 and keeps a Neutral rating on the shares.
Amgen price target raised to $440 from $384 at Canaccord
Canaccord analyst Gary Nachman raised the firm’s price target on Amgen (AMGN) to $440 from $384 and keeps a Hold rating on the shares. The firm said Q3 had solid…
Amgen price target raised to $465 from $405 at Citi
Citi raised the firm’s price target on Amgen (AMGN) to $465 from $405 and keeps a Buy rating on the shares. The firm says the company’s Q3 report shows its…
Amgen price target raised to $460 from $430 at Wells Fargo
Wells Fargo analyst Mohit Bansal raised the firm’s price target on Amgen (AMGN) to $460 from $430 and keeps an Equal Weight rating on the shares. The firm says strong…